Skip to main content

Market Overview

Omega Therapeutics Touts Encouraging Preclinical Data In Liver Cancer Animal Models

Share:
Omega Therapeutics Touts Encouraging Preclinical Data In Liver Cancer Animal Models
  • Omega Therapeutics Inc (NASDAQ: OMGA) has presented new preclinical data on its lead product candidate, OTX-2002, in multiple models of hepatocellular carcinoma.
  • In non-human primates, treatment with OTX-2002 resulted in a durable reduction of MYC mRNA levels in the liver consistent with previous in vitro and in vivo studies.
  • OTX-2002 treatment decreased c-Myc mRNA, protein levels, and cell viability in multiple HCC cell lines while sparing normal cells.
  • Related: Omega Therapeutics Submits IND For Liver Cancer Candidate.
  • OTX-2002 significantly reduced tumor growth in HCC xenografts models.
  • OTX-2002 treatment is associated with decreased expression of the immune checkpoint factor PD-L1 in HCC cells, suggesting a potential role for combination therapy with immune checkpoint inhibitors.
  • Combining OTX-2002 with the existing standard of care therapies for HCC resulted in further reduction of cell viability and tumor burden in both in vitro and in vivo HCC models.
  • Price Action: OMGA shares are down 1.41% at $4.20 during the market session on the last check Thursday.
 

Related Articles (OMGA)

View Comments and Join the Discussion!

Posted-In: Briefs Preclinical PhaseBiotech News Penny Stocks Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com